PT Gudang Garam Tbk (IDX:GGRM)
Indonesia · Delayed Price · Currency is IDR | Market Cap | 17.08T |
| Revenue (ttm) | 93.01T |
| Net Income (ttm) | 172.45B |
| Shares Out | 1.92B |
| EPS (ttm) | 89.71 |
| PE Ratio | 98.93 |
| Forward PE | 7.23 |
| Dividend | 500.00 (5.67%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 408,000 |
| Average Volume | 519,905 |
| Open | 8,800.00 |
| Previous Close | 8,825.00 |
| Day's Range | 8,700.00 - 8,925.00 |
| 52-Week Range | 8,425.00 - 17,200.00 |
| Beta | 0.21 |
| RSI | 41.11 |
| Earnings Date | Jul 31, 2025 |
About Revance Therapeutics
PT Gudang Garam Tbk, together with its subsidiaries, engages in the manufacture and sale of cigarettes in Indonesia and internationally. The company operates through Cigarettes, Paperboards, Infrastructure, and Others segments. It offers hand-rolled, machine-made, and klobot clove cigarettes. The company markets its products under the Gudang Garam Family, Surya Family, and GG Family brand names. It is also involved in trading business; and provision of safety protective equipment, and investment, toll road and construction services. In addition... [Read more]
Financial Performance
In 2024, PT Gudang Garam Tbk's revenue was 98.66 trillion, a decrease of -17.06% compared to the previous year's 118.95 trillion. Earnings were 980.81 billion, a decrease of -81.58%.
Financial StatementsNews
Gudang Garam: A Sell On Unexciting Outlook And Demanding Valuations
Gudang Garam's size is a disadvantage in Indonesia's tobacco market, facing higher taxes vs. smaller competitors like Wismilak Inti Makmur. Learn more on GDNGY stock here.